EMMESSAR BIOTECH & NUTRITION LTD						
UNAUDITED FINANCIAL RESULTS AS ON 30TH SEPTEMBER 2014 [REVISED]						
(Rs. In Lakhs)						
Particulars	Current Qtr Ended 30.09.2014 Unaudited	Preceding Qtr Ended 30.06.2014 Unaudited	Corresponding Qtr Ended 30.09.2013 Unaudited	Half Year Ended 30.09.2014 Unaudited	Corresponding Half Year Ended 30.09.2013 Unaudited	Previous Yea Ended 31.03.2014 Audited
01) Sales / Income from Operations (Gross)	41.79	25.86 0.34	5.92	67.65	69.89	140.00
Less: Excise Duty (a) Net Sales / Income from operations	3.28 38.51	0.34 25.52	0.16 5.76	3.62 64.03	1.19	3.14 136.86
(b) Other Income	-	-	-			-
Total Income 02) Expenditure	38.51	25.52	5.76	64.03	68.70	136.86
(a) (Increase) / Decrease in stock in trade	(26.30)	(12.25)	(8.41)	(38.55)	(0.18)	(9.08
(b) Consumption of Raw materials	26.96	17.63	10.08	44.59	25.52	53.32
(c) Purchase of Traded goods (d) Employee Cost	5.99	5.96	0.57 4.96	11.95	0.76 9.15	0.67 22.77
(e) Depreciation	1.71	1.71	1.75	3.42	3.50	19.59
(f) Other Expenditure	38.96	21.92	19.51	60.88	37.12	75.54
Total Expenditure (a to f)  03) Profit from Operations before Other Income	47.32 (8.81)	34.97 (9.45)	28.46 (22.70)	82.29 (18.26)	75.87 (7.17)	162.81 (25.95
Interest & Exceptional items (1 - 2)	(0.01)	(5.40)	(22.70)	(10.20)	(1.17)	(20.50
04) Other Income	1.66	2.92	7.68	4.58	8.23	9.22
05) Profit before Interest and Exceptional Items (3 + 4)	(7.15)	(6.53)	(15.02)	(13.68)	1.06	(16.73
06) Interest	(7.15)	(0.53)	(15.02)	(13.00)	1.06	(16.73
07) Profit after Interest but before						
Exceptional Items (5 - 6)	(7.15)	(6.53)	(15.02)	(13.68)	1.06	(16.73
08) Exceptional Items 09) Profit / (-) Loss from Ordinary Activities	-	-	-	-	-	-
Before Taxation (7 + 8)	(7.15)	(6.53)	(15.02)	(13.68)	1.06	(16.73
10) Tax Expense	-	-	-	-	2.90	13.98
<ol> <li>Net Profit / (Loss) from Ordinary Activities after Taxation (9 - 10)</li> </ol>	(7.15)	(6.53)	(15.02)	(13.68)	(1.84)	(30.71
12) Extraordinary Item (net of tax expense)	(7.13)	(0.55)	(13.02)	(13.00)	(1.04)	(30.7
<ol> <li>Net Profit / Loss for the period (11-12)</li> </ol>	(7.15)	(6.53)	(15.02)	(13.68)	(1.84)	(30.7
14) Paid-up Equity Share Capital	499.61	499.61	499.61	499.61	499.61	499.61
(Face Value of the share) 15) Reserves excluding Revaluation Reserve	10.00	10.00	10.00	10.00	10.00	10.00
as per Balance Sheet of previous						
accounting year	(0.44)	(0.40)	(0.00)	(0.07)		
Earning per Shares     Basic & diluted EPS before Extraordinary	(0.14)	(0.13)	(0.30)	(0.27)	(0.04)	(0.61
items for the period, for the year to date & for the previous year (not to be annulised) b) Basic & diluted EPS after Extraordinary items for the period, for the year to date & for the previous year (not to be annulised) PART II						
A. PARTICULARS OF SHAREHOLDINGS						
Public Shareholding	0400704			0010000	00.40000	000074
No. of Shares     Percentage of Shareholding	2183781	2290916 45.85	2340026 46.84	2340026 46.84	2340026 46.84	230271
2) Promoters & Promoters Group Shareholding	43.71	40.00	40.04	40.04	40.04	40.0
a) Pledged / Encumbered						
<ul> <li>No. of Shares</li> <li>Percentage of Shares (as % of the total share-</li> </ul>	Nil Nil	Nil Nil	Nil Nil	Nil Nil	Nil Nil	Nil Nil
- Percentage of Shares (as % of the total share- holding of the Promoter & Promoter Group)	INII	IVIII	INII	NII	IVII	INII
- Percentage of Shares (as % of the total	Nil	Nil	Nil	Nil	Nil	Nil
Share Capital of the Company) b) Non Encumbered		-				
b) Non Encumbered - No. of Shares	2812319	2705184	2656074	2656074	2656074	269338
- Percentage of Shares (as % of the total share-	100%	100%	100%	100%	100%	1009
holding of the Promoter & Promoter Group)	56 29	54 15	53 16	53 16	53 16	53.9
<ul> <li>Percentage of Shares (as % of the total Share Capital of the Company)</li> </ul>	56.29	54.15	53.16	53.16	53.16	53.9
			I.	Three	Months ended: 3	30.09.2014
B. INVESTORS COMPLAINTS					Nil	
Pending at the beginning of the quarter Received during the quarter					NII NII	
Disposed of during the quarter					Nil	
Remaining unresolved at the end of the quarter.					Nil	
* The above results were reviewed by the Audit Cor						
* The Statutory Auditors have carried out a Limited Review of the results for the						
quarter ended September 30, 2014.  * The above Un-Audited Results were taken on record at the meeting of the Board of						
<ul> <li>The above Un-Audited Results were taken on reconstructions held on 30th October, 2014.</li> </ul>	oru at the mee	surig of the B	uaru Of			
Directors field on Julii October, 2014.						
Mumbai By order of the Board						
30th October, 2014 MSR Ayyangar						
Managing Director						

## **EMMESSAR BIOTECH & NUTRITION LIMITED**

Quarter ended Segment wise Revenue Results and Capital Employed [REVISED]						
					[Rs. In La	akhs]
Particulars	Current Qtr Ended 30.09.2014 Unaudited	Preceding Qtr Ended 30.06.2014 Unaudited	Corresponding Qtr Ended 30.09.2013 Unaudited	Half Year Ended 30.09.2014 Unaudited	Corresponding Half Year Ended 30.09.2013 Unaudited	Previous Year Ended 31.03.2014 Audited
1. Segment Revenue						
(Net Sales / Income)						
a. Healthcare	11.51	7.34	5.76	18.85	23.69	46.22
b. Fine Chemicals	27.00	18.18	-	45.18	45.01	90.64
c. Others	1.66	2.92	7.68	4.58	8.23	9.22
Total:	40.17	28.44	13.44	68.61	76.93	146.08
Less: Inter Segment Revenue	-	-	-	-	-	-
Net Sales / Income from Operations	40.17	28.44	13.44	68.61	76.93	146.08
2. Segment Results (Profit / Loss)						
before Tax and Interest						
a. Healthcare	5.60	3.98	1.55	9.58	13.11	32.06
b. Fine Chemicals	2.81	2.12	-	4.93	15.93	23.65
c. Others	1.66	2.92	7.68	4.58	8.23	0.80
Total:	10.07	9.02	9.23	19.09	37.27	56.51
Less:						
Interest	_	-	-	-	-	_
Other Unallocable Expenditure						
net off Unallocable Income	17.22	15.55	24.25	32.77	36.21	73.24
Total Profit before Tax	(7.15)	(6.53)	(15.02)	(13.68)	1.06	(16.73)
3. Capital Employed						
(Segment Assets - Segment Liabilities)						
a. Healthcare	16.49	28.81	21.22	16.49	21.22	11.42
b. Fine Chemicals	12.66	(7.85)	(5.55)	12.66	(5.55)	14.92
c. Others	(40.06)	(26.43)	(1.65)	(40.06)	(1.65)	(19.46)
Total:	(10.91)	(5.47)	14.02	(10.91)	14.02	6.88

**Note:** The Fixed Assets are employed for the general enterprise and are not segmental in nature.

The above results were taken on record at a meeting of the Board of Directors held on 30th October, 2014.

Mumbai 30th October, 2014 By order of the Board MSR Ayyangar Managing Director

## **EMMESSAR BIOTECH & NUTRITION LTD** Statements of Assets & Liabilities (Rs. In Lakhs) **Particulars** As at 30.09.2014 As at 31.03.2014 **EQUITY AND LIABILITIES SHAREHOLDER'S FUNDS:** (a) Share Capital 499.61 499.61 (b) Reserves & Surplus (364.07)(341.55)135.54 158.06 **Sub-total Shareholder's funds Non-current Liabilities** (a) Long-term borrowings 8.17 7.08 (b) Deferred tax liabilities (net) 13.98 13.98 **Sub-total Non-current liabilities** 22.15 21.06 **Current Liabilities** 3 (a) Short-term borrowings 10.00 15.07 (b) Trade payables 60.53 (c) Other current Liabilities 29.99 27.62 (d) Short-term provisions 0.49 **Sub-total Current Liabilities** 100.52 43.18 222.30 **TOTAL EQUITY AND LIABILITIES** 258.21 В **ASSETS** Non-current Assets 1 (a) Fixed Assets 145.91 158.00 (b) Non-current investments 0.54 0.54 7.40 (c) Long-term loans and advances 7.41 **Sub-total Non-current Assets** 153.86 165.94 **Current Assets** (a) Inventories 84.93 33.20 (b) Trade Receivables 4.76 17.01 (c) Cash & Cash equivalents 5.61 3.04 (d) Short-term loans and advances 9.05 3.11

Sub-total Current Assets	104.35	56.36
TOTAL ASSETS	258.21	222.30